HIF prolyl-hydroxylase inhibitor
Clash Royale CLAN TAG#URR8PPP
Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitors (HIF-PHIs) also known as Hypoxia-Inducible Factor stabilizers (HIF stabilizers) are members of a class of new drugs that act by inhibiting prolyl hydroxylase which is responsible to break down the hypoxia-inducible factor (HIF) under normoxic conditions.
As of 2008[update] they are being investigated for treatment of anemia, chronic kidney disease,[1] cancer,[2] and for their effects on heart tissue[3] and others.[4]
Research conducted in mice suggests that they may increase hippocampal memory by increasing erythropoietin expression.[5]
They act by inhibiting HIF prolyl-hydroxylase enzymes.
See also
- Daprodustat
- Molidustat
- Roxadustat
- Vadadustat
- Desidustat
References
^ Warnecke, C.; Griethe, W.; Weidemann, A.; Jurgensen, J. S.; Willam, C.; Bachmann, S.; Ivashchenko, Y.; Wagner, I.; Frei, U.; Wiesener, M.; Eckardt, K.-U. (2003). "Activation of the hypoxia-inducible factor pathway and stimulation of angiogenesis by application of prolyl hydroxylase inhibitors". The FASEB Journal. 17: 1186–8. doi:10.1096/fj.02-1062fje. PMID 12709400..mw-parser-output cite.citationfont-style:inherit.mw-parser-output qquotes:"""""""'""'".mw-parser-output code.cs1-codecolor:inherit;background:inherit;border:inherit;padding:inherit.mw-parser-output .cs1-lock-free abackground:url("//upload.wikimedia.org/wikipedia/commons/thumb/6/65/Lock-green.svg/9px-Lock-green.svg.png")no-repeat;background-position:right .1em center.mw-parser-output .cs1-lock-limited a,.mw-parser-output .cs1-lock-registration abackground:url("//upload.wikimedia.org/wikipedia/commons/thumb/d/d6/Lock-gray-alt-2.svg/9px-Lock-gray-alt-2.svg.png")no-repeat;background-position:right .1em center.mw-parser-output .cs1-lock-subscription abackground:url("//upload.wikimedia.org/wikipedia/commons/thumb/a/aa/Lock-red-alt-2.svg/9px-Lock-red-alt-2.svg.png")no-repeat;background-position:right .1em center.mw-parser-output .cs1-subscription,.mw-parser-output .cs1-registrationcolor:#555.mw-parser-output .cs1-subscription span,.mw-parser-output .cs1-registration spanborder-bottom:1px dotted;cursor:help.mw-parser-output .cs1-hidden-errordisplay:none;font-size:100%.mw-parser-output .cs1-visible-errorfont-size:100%.mw-parser-output .cs1-subscription,.mw-parser-output .cs1-registration,.mw-parser-output .cs1-formatfont-size:95%.mw-parser-output .cs1-kern-left,.mw-parser-output .cs1-kern-wl-leftpadding-left:0.2em.mw-parser-output .cs1-kern-right,.mw-parser-output .cs1-kern-wl-rightpadding-right:0.2em
^ Ivan, Mircea (2006). "HIF-PROLYL hydroxylase inhibitors: From basic science to clinical trials" (PDF). MÆDICA - a Journal of Clinical Medicine. 1 (2): 67–69. ISSN 1841-9038.
[permanent dead link]
^ Nangaku, M.; Izuhara, Y.; Takizawa, S.; Yamashita, T.; Fujii-Kuriyama, Y.; Ohneda, O.; Yamamoto, M.; Van Ypersele De Strihou, C.; et al. (2007). "A Novel Class of Prolyl Hydroxylase Inhibitors Induces Angiogenesis and Exerts Organ Protection Against Ischemia". Arteriosclerosis, Thrombosis, and Vascular Biology. 27 (12): 2548–2554. doi:10.1161/ATVBAHA.107.148551.
^ "FibroGen Reports New Research on Development of HIF Prolyl Hydroxylase Inhibitors Related to Endothelial Progenitor Cells, Anti-Inflammation, Cytoprotection and Erythropoiesis". drugs.com. 2008.
^ Adamcio, B; Sperling, S; Hagemeyer, N; Walkinshaw, G; Ehrenreich, H (2010). "Hypoxia inducible factor stabilization leads to lasting improvement of hippocampal memory in healthy mice". Behavioural Brain Research. 208 (1): 80–4. doi:10.1016/j.bbr.2009.11.010. PMID 19900484.
See also
- Hypoxia-inducible factors#As a therapeutic target
 | This pharmacology-related article is a stub. You can help Wikipedia by expanding it. |
